2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes.
Tag Archive for: artificial intelligence
As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care, and pharma and biotech companies’ increased investment in “access,” but there are two trends that are at the top of the “what we’re watching” list for 2024.
Many telehealth policies expanded during the pandemic have been extended through December 31, 2024. Beyond that, policymakers will need to make hard decisions or continue with temporary extensions. Either way, a range of changes in telehealth are coming and will impact reimbursement policies, technology infrastructure, privacy, provider and patient/member adoption, and economic factors.
If you’re a student of history – or recently saw the popular movie “Oppenheimer”, you know just how pivotal of a figure J. Robert Oppenheimer is. He is forever linked to the development of one of the most powerful and dangerous creations in history – the atomic bomb. Drawing parallels to artificial intelligence, Faruk Capan of EVERSANA explains the ethical and societal impacts of the technology.
For the first time, the 300,000 U.S. primary care physicians can now be equipped to provide quantitative, point-of-care testing for all types of skin cancer.
The healthcare industry is acutely aware of the elevated compliance concerns involved with artificial intelligence and machine learning, and its governing organizations are taking swift action to address these challenges. In fact, the latest guidelines proposed by international regulatory organizations such as the FDA, European Union (EU), and European Medicines Agency (EMA) are poised to reshape the lifesciences industry, especially for clinical trials.
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
2024 will continue to see Big Tech companies enter the artificial intelligence-based drug discovery space, potentially disrupting the biopharma industry. That was the consensus of panelists at a Tuesday session on AI and machine learning held by the Biotech Showcase, co-located with the 42nd J.P. Morgan Healthcare Conference.
